FIXED COMBINATION OF BECLOMETHASONE PROPIONATE AND FORMOTEROL - A PROMISING ALTERNATIVE IN THE THERAPY OF BRONCHIAL ASTHMA


E.V. Nazarova, O.M. Kurbacheva

FSBI SSC Institute of Immunology FMBA of Russia, Moscow
Traditionally, bronchial asthma (BA) was considered as a disease of mainly large and medium bronchi, and small airways has received little attention. Recently, however, strong evidence that the inflammatory process in asthma captures distal lower respiratory tract was found. Currently, inhaler devices are active developed to improve the delivery of anti-inflammatory drugs on the periphery of the lungs. This provides the potential for the improvement of results of long-term treatment of patients with bronchial asthma. In the case of ineffectiveness of asthma therapy with low-dose inhaled glucocorticosteroids (IGCS), modern guidelines recommend the combination of inhaled corticosteroids and LABA (long-acting β2-agonists) as the "gold" standard, and note the benefits of application of two drugs in a single inhaler. The only drug that combines inhaled corticosteroids and LABA in a single inhaler with ultrafine spray represented on the Russian market is Foster, consisting of beclomethasone propionate and formoterolfumarate.

About the Autors


E.V. Nazarova – PhD in Medical Sciences, Senior Scientist, allergist-immunologist, FSBI SSC Institute of Immunology FMBA of Russia
O.M. Kurbacheva – MD, Prof., Head of the department of clinical and epidemiological research № 89, FSBI SSC Institute of Immunology FMBA of Russia, Moscow


Similar Articles


Бионика Медиа